TheiaLife Sciences
- Biotech or pharma, therapeutic R&D
Theialife has developed the world’s first oral drug for Myopia Control (Ph 3 ready). 12+ years clinical usage in Denmark with 1200 children treated, results published in BJO in 2022. Multi $ billion market potential. 20 years IP remains.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}